BPMC News and Press, Blueprint Medicines Corporation From 05/04/23

2023-05-04 07:55:35 ET Blueprint Medicines press release ( NASDAQ: BPMC ): Q1 GAAP EPS of -$2.15 beats by $0.51 . Revenue of $63.28M (+0.9% Y/Y) beats by $21.43M . Cash Position: As of March 31, 2023, cash, cash equivalents and investments were $961.3 million, ...

Blueprint Medicines Reports First Quarter 2023 Results PR Newswire -- Achieved $39.1 million in AYVAKIT ® /AYVAKYT ® (avapritinib) net product revenues and $63.3 million in total revenues in the first quarter of 2023 -- -- Raising 2023 AYVAKIT...

2023-04-29 16:00:00 ET With the first trading day in May coming on Monday, many pharmaceutical companies will be hoping their returns fare better than they did in April. The iShares U.S. Pharmaceuticals ETF ( IHE ) returned a paltry 1.6% in April. The ETF's top two holdings are ...

Blueprint Medicines to Present New Clinical Data Across Broad Precision Therapy Pipeline at 2023 ASCO Annual Meeting PR Newswire CAMBRIDGE, Mass. , April 26, 2023 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC) today announced the acceptance of cli...

Blueprint Medicines to Report First Quarter 2023 Financial Results on Thursday, May 4, 2023 PR Newswire CAMBRIDGE, Mass. , April 20, 2023 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC) today announced that it will host a live conference call and w...

2023-03-28 17:48:21 ET The US FDA has lifted a partial clinical hold placed in February on Blueprint Medicines' ( NASDAQ: BPMC ) early stage candidate BLU-222 for CDK2-vulnerable cancers. The hold was due to visual adverse events, such as short lasting, reversible epis...

Blueprint Medicines Announces Lift of Partial Clinical Hold on Phase 1/2 VELA Trial of BLU-222 PR Newswire CAMBRIDGE, Mass. , March 28, 2023 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC) today announced that the U.S. Food and Drug Administration ...

2023-03-27 10:16:14 ET Summary Blueprint Medicines' avapritinib demonstrated significant improvements in patient-reported symptoms and disease burden in indolent systemic mastocytosis (ISM). Avapritinib's safety profile in the trial was well-tolerated, with fewer serious adverse e...

2023-03-23 08:36:09 ET ORIC Pharmaceuticals ( NASDAQ: ORIC ) added ~5% pre-market Thursday after H.C. Wainwright upgraded the cancer-focused biotech to Buy from Neutral, adding its solid tumor candidate ORIC-114 to the firm's valuation model. The upgrade comes as ORIC pr...

The following slide deck was published by Blueprint Medicines Corporation in conjunction with this event. For further details see: Blueprint Medicines (BPMC) Presents At AAAAI Conference